Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: The Complete Health Improvement Program; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: Not listed
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Glaucoma
Interventions: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Glendale, California • Newport Beach, California • Pasadena, California + 11 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Wenatchee, Washington

Conditions: Glaucoma
Interventions: MEMS cap; Device
Lead sponsor: Robin, Alan L., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers, Profiling performance; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 3
States / cities: Palo Alto, California • San Francisco, California • Durham, North Carolina

Conditions: Pulmonary Embolism
Interventions: nitric oxide; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more

Conditions: Prehypertension, Hypertension
Interventions: Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 45 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Hypertension
Interventions: Questionnaire; Other
Lead sponsor: Withings; Industry
Eligibility: 21 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension
Interventions: Healthy Behavior Texts, No healthy behavior texts, BP Monitoring Daily Via Text Messaging, BP Monitoring Weekly Via Text Messaging, Physician appointment and transportation scheduling, No physician appointment and transportation scheduling; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
Interventions: Blood Gas, Pulmonary Exercise Test, Spirometry, Breath Condensate Collector; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hypertension in Pregnancy
Interventions: Amlodipine, NIFEdipine ER; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older · Female only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glendale, Arizona

Conditions: Metabolic Syndrome X, Dyslipidemias
Interventions: Moderate Fat and Moderate Carbohydrate Diet, Low Fat and High Carbohydrate Diet; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 30 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Blood Pressure, High
Interventions: Ramipril and hydrochlorothiazide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more

Conditions: Esophageal Varices, Liver Cirrhoses, Bleeding Esophageal Varices, Upper Gastrointestinal Bleeding
Interventions: Octreotide; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Jacksonville, Florida • Chicago, Illinois • Columbus, Ohio + 5 more

Conditions: Preeclampsia, Hypertensive Disorder of Pregnancy
Interventions: Progesterone supplementation; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 642 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Glaucoma
Interventions: Aflibercept Injection, Ahmed Tube Surgery; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension, Renal Insufficiency, Chronic
Interventions: Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: brinzolamide 1.0%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pre-Eclampsia
Interventions: L-Arginine Supplementation; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 16
States / cities: Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Therapeutic Intra-Vascular UltraSound (TIVUS™) System; Device
Lead sponsor: SoniVie Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: San Diego, California • Ann Arbor, Michigan • New York, New York + 1 more

Search by objective public record fields.

Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Observational Study of How Patients Take Eye Drops

Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation

Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Nebivolol and the Endothelin (ET)-1 System

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Withings Devices Follow-up Study - Hypertension

Reach Out: Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health Systems

Biomarkers in the Evaluation of Chronic Lung Disease

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Progesterone Preeclampsia

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

Glomerular Injury of Preeclampsia

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

TReatment Of Pulmonary HYpertension 1-US Study